Vivos Therapeutics (VVOS): Customer Relationships That Drive a Services-Plus-Hardware Model

Vivos Therapeutics operates a dual revenue model that combines device sales (oral appliances and guides) with services and licensing to trained dental providers who sell and administer the Vivos Method. The company monetizes through point-in-time product sales, recurring subscription services (practice management and billing), and licensed “right to sell” arrangements that generate ongoing service revenue from VIP enrollments and provider fees. For investors, the essential dynamic is a small-cap medical-devices company monetizing both hardware and continuing services while carrying meaningful contract liabilities tied to ongoing service obligations.
Explore how these customer relationships map to commercial risk and upside at https://nullexposure.com/.

How Vivos actually sells: a concise commercial thesis

Vivos combines three revenue levers: (1) one-off appliance sales recognized at shipment; (2) subscription services such as BIS (billing and practice management); and (3) licensed rights and VIP enrollment fees that are recognized over the estimated active life of trained providers. This structure produces a mix of spot revenues and durable, service-driven cash flows, while creating balance-sheet exposure in the form of unearned revenue recognized as contract liabilities. The company’s FY2025 operating profile reflects a small revenue base (Revenue TTM $17.3M) and negative operating profitability, making partner economics and recurring revenue cadence central to any valuation argument.

Company-level commercial constraints and what they imply

Treat these as firm-level operating signals rather than relationship-specific facts. Collectively they describe Vivos’ contracting posture, concentration, and maturity.

Contracting posture — mixed: Vivos recognizes spot product revenue at shipment while also offering monthly subscription services (BIS) and recognizing “right to sell” revenue over the estimated active life of VIP providers. This hybrid posture produces immediate cash from appliance sales and deferred revenue representing future service obligations.
Revenue criticality and balance-sheet impact — material: The company reports unearned revenue as a significant liability, which signals that a meaningful portion of cash collected precedes delivered services and therefore requires active fulfillment to avoid churn or revenue reversal.
Geographic exposure — North America-centric with selective APAC/EMEA reach: Sales are concentrated in the U.S. and Canada with limited presence in Australia and select European/Asian markets, implying near-term growth will depend largely on North American customer expansion.
Role friction — licensor, seller, and service provider: Vivos operates simultaneously as licensor of its method, seller of hardware, and service provider (VIP enrollments and billing services), producing cross-selling benefits but also operational complexity in training, compliance, and provider support.
Customer lifetime and revenue recognition — longer tails: The company recognizes “right to sell” revenue over multi-year estimated customer lives (14–27 months historically), indicating repeat purchase behavior from trained providers and a dependency on training retention to sustain revenue.
Segment mix and spend scale — hardware + services, sub-$100k per engagement: The business combines hardware and services with VIP enrollment pricing cited around $23,200, placing typical customer spend well below six-figure thresholds and suggesting numerous mid-ticket transactions rather than a few enterprise deals.

Customer relationships: deal-level snapshots

Below are concise, plain-English summaries of each relationship in the public record, with source context.

V-CO Investors LLC — Securities purchase agreement with investor/affiliate. According to Vivos’ FY2024 10-K, the company entered into a securities purchase agreement with V-CO Investors LLC on June 10, 2024; this is recorded as a financing arrangement in the company filing rather than a product-sale relationship. (Source: FY2024 10‑K filing, June 2024.)
Rebis Health Holdings — Revenue-share access to Vivos-trained dental professionals. A Sleep Review article described a partnership where Vivos provides Rebis access to licensed dental professionals trained in Vivos protocols, and Rebis receives a percentage of patient payments collected by those dental providers after fees are deducted. (Source: Sleep Review, partnership coverage, FY2025.)
SoundHealth — Clinical screening and monitoring technology integration. Industry reporting noted that Vivos will use SoundHealth’s CT-accurate facial scanning and voice biomarker tools to help clinical providers screen and monitor sleep-disorder patients, improving diagnostic throughput and treatment follow-up. (Source: Intellectia coverage of a FY2026 announcement.)
Pneusomnia clinics — Multidisciplinary clinical collaboration with trained dentists. Reporting on clinical practice trends cites ongoing collaboration between physicians and Vivos-trained dentists across the growing network of Vivos provider offices and Pneusomnia clinics to deliver combined diagnostic and orofacial myofunctional therapy. (Source: Sleep Review article on multidisciplinary therapy, FY2021.)

What these partnerships mean for growth, margin and risk

The relationship map highlights a strategy of embedding Vivos’ method into clinical workflows while layering technology and revenue-share deals to extend reach. Key implications:

Growth lever: Licensing the Vivos Method and training dental providers creates a recurring revenue base from enrollment and appliance refill/supply cycles; partnerships with tech firms like SoundHealth expand clinical screening capacity and could raise throughput per provider.
Margin implication: Hardware sales provide near-term gross margin, while subscription services and revenue-sharing deals shift contribution to recurring margin that depends on provider utilization and retention.
Operational risk: The company’s material unearned revenue balance creates execution risk—if trained providers do not remain active or patient uptake slows, Vivos must amortize or refund collected fees. Regulatory and clinical integration risk is elevated when work crosses physician and dental practice boundaries.
Concentration and scale: North American concentration constrains upside if international expansion and partner channels do not scale; mid-ticket pricing implies revenue growth requires volume expansion rather than single large contracts.

If you want a deeper partner-by-partner risk matrix and exposure map, review our methodology and service options at https://nullexposure.com/.

Investment checklist: what to monitor next

Track changes in unearned revenue on the balance sheet and disclosure around VIP activation/retention rates.
Watch partnerships that drive clinical screening capacity (e.g., SoundHealth) for measurable increases in treatment starts per provider.
Monitor geographic expansion metrics—new markets in Europe/Asia or Australia should move the revenue mix off a North America concentration.
Follow press and filings for revenue-share or licensing agreements that materially change take-rates or contract lengths with VIP providers.

Bottom line and actionable guidance

Vivos operates a services-first hardware strategy with multiple partner relationships that extend its clinical reach and product adoption. The combination of spot appliance sales, subscription services, and multi-year licensing revenue gives the company optionality, but that optionality is balanced by material deferred revenue obligations and execution risk around provider activation and cross-disciplinary adoption. For investors, the key questions are whether partnerships like Rebis and SoundHealth increase lifetime value per provider and whether Vivos can convert its North American footprint into sustainable recurring revenue growth. Learn more about mapping partner risk and revenue exposure at https://nullexposure.com/.

VVOS customer relationships